Complete Remission Rate and Adverse Ractions of Three Different Chemotherapy Regimens in the Treatment of Adult Patients with Newly Diagnosed Non-M3 AML / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To compare the complete remission rate (CRR) and adverse reaction of the 3 different chemotherapy regimens (daunorubicin, idarubicin, imported idarubicin combined with cytarabine) for the treatment of adult patients with newly diagnosed non-M3 acute myeloid leukemia (AML).</p><p><b>METHODS</b>Seventy-one adult patients with newly diagnosed non-M3 AML were divided into 3 groups: 17 cases treated with daunorubicin plus cytarabine as group A, 24 cases treated with idarubicin plus cytarabine as group B, 30 cases treated with the imported idarubicin plus cytarabine as group C. The curative effects and adverse reactions were compared among the 3 groups after treatment.</p><p><b>RESULTS</b>CCR in group C (86.67%) was significantly higher than that in group A (52.94%) and group B (70.83%), and the CRR in group B was significantly higher than that in group A (P<0.05). The incidence of adverse reaction such as nausea, vomiting, myelosuppression and infection among 3 groups were not statistically significantant (P>0.05).</p><p><b>CONCLUSION</b>The curative effect of idarubicin for the treatment of non-M3 AML patients is better than that of daunorubicin, especially the curative efficiency of imported darubicin is much higher; the adverse reaction after treatment by daunorubicin and idarubicin can be controllable, so daunorubicin and idarubicin can be used as first-line drug for the patients with AML, and patients can choose more appropriate drug according to their own economic ability.</p>

Role of Non-classical NF-κB Signaling Pathway in B Acute Lymphoblastic Leukemia / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To study the role of non-classical NF-κB signaling pathway in B acute lymphoblastic leukemia (B-ALL).</p><p><b>METHODS</b>The bone marrow samples from 48 patients with B-ALL were collected from March 2015 to March 2016. The real-time quantitative RT-PCR was used for determing mRNA expression levels of NF-κB family members; the NF-κB DNA binding activity in B-ALL cell nucleus was analyzed by ELISA; the apoptosis rate of B-ALL cells alone or co-cultured with bone marrow stromal cells (hBMSC) was determined by flow cytometry.</p><p><b>RESULTS</b>Relative expression level of mRNA for NF-κB family members, including the Rel A, Rel B, P50 and P52 in ALL-B group was statistically significantly higher than that in normal control group (P<0.05). The clinical characteristics of B-ALL patients with different NF-κB activity were not significantly different (P> 0.05); after B-ALL cells cultured alone or co-cultured, the apoptosis rate of Rel A/ Rel Bgroup was statistically significantly higher than that in Rel A/ Rel Bgroup (P<0.05); the apoptosis rate of B-ALL cells cultured alone or co-cultured with hBMSC was significantly different.</p><p><b>CONCLUSION</b>Non-classical NF-κB signal marked by Rel B can be used as a new target for B-ALL treatment.</p>